Chemotherapy Induced Peripheral Neuropathy (CIPN)
Keywords
Abstract
Description
STUDY OUTLINE: This is a single institution study. Patients with newly diagnosed breast cancer stages I to III with any biomarker status (ER, PR and HER), without preexisting peripheral neuropathy planning to receive treatment with platinum-based compounds (Carboplatin and Cisplatin) and/or taxanes (Docetaxel and Paclitaxel) and chemotherapy naive patients with gynecologic cancers including ovarian, uterine, and cervical cancer planning to receive definitive number of platinum-based compounds (carboplatin or cisplatin) and/or taxanes (docetaxel and paclitaxel) chemotherapy are potential study patients.
Subjects will be randomized into one of two treatment arms within 3 weeks of starting the offending chemotherapy agents after fulfilling the other study eligibility requirements. Arm 1 (investigational) will receive INF twice a week for six weeks by the same treating physical therapist (physical therapist #1). Arm 2 (control) will receive a standardized program of muscle stretching and strengthening exercises twice a week for 6 weeks under the supervision of treating physical therapist #1. Actual treatment time for both modalities is approximately 45 minutes. Measurements used to detect the presence and degree of peripheral neuropathy will be administered by the same assessment physical therapist (physical therapist #2) at baseline and at the end of weeks 3, 6, and 3 months post last physical therapy treatment. Assessment tools are: ultrasound imaging on the popliteal and posterior tibia artery, the 20-item Pain Quality Assessment Scale (PQAS, specifically addresses neuropathological symptomatology), the National Comprehensive Cancer Network (NCCN) Distress thermometer (DT), and the Michigan Neuropathy Screening Instrument (MNSI) will be assessed and recorded along with treatment adherence. Treating physician will be recording National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) neuropathy score and performance status at routine intervals during and after chemotherapy.
Objectives
Primary objective
• To compare the degree of neuropathy and distress between Arm 1 receiving INF therapy compared to Arm 2 receiving usual care of muscle stretching and strengthening exercises based on standardized measurements (PQAS, MNSI, NCCN DT, and AE assessment).
Secondary objectives
- To compare the Ultrasound measurements of peak systolic velocity, volume flow and pulsatility of popliteal and posterior tibia artery between the two treatment arms for assessing differences in vascular perfusion.
- To compare the rate of any dose reductions and premature chemotherapy discontinuation rates due to peripheral neuropathy between Arm 1 receiving INF therapy compared to Arm 2 receiving standardized program of muscle stretching and strengthening exercises.
- To compare subject acceptability, burden and satisfaction with the assigned physical therapy modality between the two arms based on patient satisfaction questionnaire administered at the end of treatment.
Dates
| Last Verified: | 06/30/2020 |
| First Submitted: | 08/07/2017 |
| Estimated Enrollment Submitted: | 08/31/2017 |
| First Posted: | 09/05/2017 |
| Last Update Submitted: | 07/13/2020 |
| Last Update Posted: | 07/15/2020 |
| Actual Study Start Date: | 09/27/2017 |
| Estimated Primary Completion Date: | 05/24/2021 |
| Estimated Study Completion Date: | 05/24/2021 |
Condition or disease
Intervention/treatment
Other: Arm 1: Investigational INF
Other: Arm 2: Standardized muscle stretching and strengthen
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Arm 1: Investigational INF Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow. | Other: Arm 1: Investigational INF INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain. |
| Other: Arm 2: Standardized muscle stretching and strengthen subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist | Other: Arm 2: Standardized muscle stretching and strengthen subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | Female |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Newly diagnosed stages I to III breast cancer patients with any biomarker status (ER, PR and HER) receiving treatment with platinum-based compounds (Carboplatin and Cisplatin) and/or taxanes (Docetaxel and Paclitaxel). - Chemotherapy naive patients with gynecologic cancers including ovarian, uterine, and cervical cancer planning to receive definitive number of platinum-based compounds (carboplatin or cisplatin) and/or taxanes (docetaxel and paclitaxel) chemotherapy. - Planned to receive a minimum of 4 cycles of treatment with either of the offending chemotherapy agents (a cycle of weekly paclitaxel is considered 3 doses). - Women aged ≥ 18 years at signing of informed consent - No pre-existing peripheral neuropathy (WPPN) - ECOG status 0 or 1 - Able to provide written, informed consent to participate in the study and follow the study procedures. - Cannot participate in another non-medical intervention/therapy for peripheral neuropathy - Cannot receive more than 3 weeks of treatment with implicating chemotherapy prior to start of study assigned therapy. - Able to read and comprehend English Exclusion Criteria: - Male - Preexisting peripheral neuropathy. - Previous exposure to any of the implicated chemotherapy agents within the last 5 years (platinum-based compounds, vinca alkaloids and/or taxanes) that could potentially cause peripheral neuropathy - Evidence of significant medical illness, or psychiatric illness/social situation that would, in the investigator's judgment, make the patient inappropriate for this study. - Stage IV or metastatic breast cancer - Any physical or neurological disability that would preclude patients from participating in physical therapy |
Outcome
Primary Outcome Measures
1. Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on the PQAS score. [upto 3 months post completion of assigned treatment]
2. Descriptive Statistics to measure the degree of distress in the two arms based on NCCN- DT [upto 3 months post completion of assigned treatment]
3. Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on MSNI scores [upto 3 months post completion of assigned treatment]
4. Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on CTCAE grading [upto 3 months post completion of assigned treatment]
Secondary Outcome Measures
1. Measure the peak systolic velocity on ultrasound imaging in the popliteal and posterior tibia artery in the two arms. [upto 3 months post completion of assigned treatment]
2. Measure the rate of premature chemotherapy discontinuation due to peripheral neuropathy by treatment group [upto 3 months post completion of assigned treatment]
3. Measure the rate of dose reductions in chemotherapy due to peripheral neuropathy by treatment group [upto 3 months post completion of assigned treatment]
4. Questionnaire to survey patients on acceptability, satisfaction and burden of treatment [upto 3 months post completion of assigned treatment.]
